Twinbeech Capital LP Bei Gene, Ltd. Transaction History

Twinbeech Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $1.15 Million - $1.47 Million	5,347 New	5,347 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $1.16 Million - $1.78 Million	8,791 New	8,791 $1.19 Million
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $218,459 - $310,529	-1,793 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $207,593 - $373,553	1,793 New	1,793 $297,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.